Drugs / OC-10X
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01869933 | Apr → Jun 2013 | proliferative diabetic retinopathy | OcuCure Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02735369 | Dec 2014 → Oct 2016 | proliferative diabetic retinopathy | OcuCure Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-10X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02735369 ↗ |
| Action | Inhibit | “tubulin inhibition using OC-10X has promise as a new therapeutic approach” NCT01869933 ↗ |
| Route | Topical | “When administered as a topical eye drop” NCT01869933 ↗ |